KRAS and adenocarcinoma: On the other hand, a growing body of evidence suggests that targeting C-RAF could be a promising therapeutic strategy based on its efficiency in K-Ras and Trp53 mutant mice models of lung [77] and pancreatic ductal [78] adenocarcinomas.